Thelansis

  Remedy Pharmaceuticals, a pioneer in stroke drug development, has announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Division (OOPD) has granted Orphan Drug Designation to CIRARA for treating large territory acute ischemic stroke, including large hemispheric infarctions (LHI). According to Sven Jacobson, CEO of Remedy Pharmaceuticals, this designation highlights the unique mechanisms and universally poor outcomes of large territory ischemic strokes compared to smaller strokes. Publish Date: 22-10-2024   Source: Remedy Pharmaceuticals Acute ischemic stroke (AIS) occurs when a blood vessel supplying the brain becomes obstructed, resulting in a significant reduction or cessation of blood flow to the affected area. Stroke stands as one of the foremost contributors to mortality and disability across the globe. Modifiable risk factors encompass a range of health conditions and lifestyle factors that individuals have the potential to influ...

  Acute Ischemic Stroke is characterized by the impact of an obstruction within a blood vessel supplying blood to the brain. Stroke is one of the leading causes of death and disability worldwide. The blockage of blood flow to the brain inevitably causes acute ischemic stroke. Once the tissue oxygenation starts, depending on the time elapsed, the patient's situation changes—the lesser the time, the better the prognosis. At the cellular level, the sudden interruption or blockage of blood flow to the brain due to a blood clot (thrombus) or a plaque (fatty deposits) deprives the brain tissue of the necessary nutrients and oxygen, which leads to irreversible brain tissue damage. Ischemic stroke causes mitochondrial cell death. For AIS treatment, tPA is the gold standard and associated with improved clinical patient outcomes. The sooner the IV tPA is administered after the onset of stroke symptoms, the better the outcome. Blood-brain barrier (BBB) disruption in acute ischemic stroke ...

  Acute Ischemic Stroke is characterized by the impact of an obstruction within a blood vessel supplying blood to the brain. Stroke is one of the leading causes of death and disability worldwide. The blockage of blood flow to the brain inevitably causes acute ischemic stroke. Once the tissue oxygenation starts, depending on the time elapsed, the patient's situation changes—the lesser the time, the better the prognosis. At the cellular level, the sudden interruption or blockage of blood flow to the brain due to a blood clot (thrombus) or a plaque (fatty deposits) deprives the brain tissue of the necessary nutrients and oxygen, which leads to irreversible brain tissue damage. Ischemic stroke causes mitochondrial cell death. TPA is the gold standard for AIS treatment and is associated with improved clinical patient outcomes. The sooner the IV tPA is administered after stroke symptoms, the better the result.   Blood-brain barrier (BBB) disruption in acute ischemic stroke varie...